In particular, our results indicate that erbB-2-positive tumor cells derived from MMTV-erbB-2 transgenic mice were sensitive to lapatinib in vitro and the molecular signaling was specifically inhibited in accordance with erbB-2/EGFR-targeting therapeutics. This evidence concerns the gene ERBB2 and neoplasm.